Lumakras Improves Outcomes, Quality of Life in Patients With Lung Cancer Subtype

September 14th 2022

Lumakras outperformed chemotherapy in reducing the risk of progression or death and improving quality of life for patients with KRAS G12C-mutated non-small cell lung cancer, study results showed.

Presurgical Opdivo-Yervoy Combo Has ‘Very Strong Potential’ to Be Standard of Care for Subgroup of Patients With Colon Cancer

September 14th 2022

None of the more than 100 evaluable patients with mismatch repair deficient colon cancer have experienced disease recurrence after treatment with presurgical Opdivo plus Yervoy, according to study results.

Second-Line Treatment With Libtayo May Improve Long-Term Survival in Subset of Patients With Cervical Cancer

September 14th 2022

Treatment with Libtayo may improve survival over a 30-month period with no new side effects in patients with recurrent or metastatic cervical cancer, opening the doors for an immunotherapy option for these patients.

Longer Hormone Therapy After Main Treatments Delays Prostate Cancer Metastasis

September 13th 2022

Two years of the hormone treatment androgen-deprivation therapy (ADT) after radiotherapy and radical prostatectomy tended to improve metastasis-free survival for patients with prostate cancer, study results showed.

Tumor-Infiltrating Lymphocyte Decreases Death Risk in Unresectable Skin Cancer

September 13th 2022

The use of a tumor-infiltrating lymphocyte therapy led to better outcomes than treatment with Yervoy in patients with unresectable, treatment-refractory stage 3/4 melanoma, a type of skin cancer, study results showed.

Adding Keytruda to a Combination of Abiraterone Acetate Plus Prednisone Continues to Demonstrate Anti-Tumor Activity in a Group of Patients With Prostate Cancer

September 12th 2022

With nearly one-year of additional follow-up, adding Keytruda to the combination of abiraterone acetate and the steroid prednisone shows continued benefit in men with metastatic castration-resistant prostate cancer.

Adding Cabometyx to Immunotherapy Combination Improves Outcomes for Advanced Kidney Cancer

September 12th 2022

The addition of Cabometyx to the current standard-of-care frontline regimen of Opdivo plus Yervoy improved progression-free survival outcomes in patients with advanced kidney cancer.

Lenvima Plus Keytruda Bests Chemotherapy for Advanced Endometrial Cancer

September 12th 2022

Lenvima plus Keytruda improved survival outcomes for patients with pretreated advanced endometrial cancer, according to recent clinical trial data.

CAR-T Cell Therapy Shows Promise in Relapsed/Refractory Solid Cancers

September 11th 2022

BNT211-01, a novel CAR-T cell therapy, was efficacious in treating patients with CLDN6-positive, relapsed/refractory solid cancers, according to a small clinical trial.

Trodelvy May Fulfill Unmet Need for Subset of Patients With Metastatic Breast Cancer

September 10th 2022

Compared to physician’s choice of treatment, Trodelvy improved survival and quality of life in pretreated patients with HR positive/HER2 negative metastatic breast cancer.

Adding the Novel Drug Oleclumab to Imfinzi and Chemotherapy Fails to Improve TNBC Outcomes

September 9th 2022

Adding the novel drug oleclumab to Imfinzi and chemotherapy for the frontline treatment of advanced triple-negative breast cancer did not improve clinical outcomes, according to recent study findings.

Rubraca Staves Off Disease Progression Better Than Chemotherapy in BRCA-Mutant Relapsed Ovarian Cancer, Research Shows

September 9th 2022

Rubraca improved progression-free survival in patients with BRCA1/2-mutant, platinum-sensitive, relapsed ovarian cancer, according to findings from the ARIEL4 clinical trial.

Survivorship Program Increases Satisfaction, Improves Quality of Life in Recurrent Breast Cancer

October 2nd 2019

“Survivors living with recurrent breast cancer have unique needs and programs that address these needs can enhance patient satisfaction,” the study authors wrote.

Addition of CDK4/6 Inhibitors to Faslodex Improves Survival in Breast Cancer Subgroup

September 30th 2019

Two studies showed that adding a CDK4/6 inhibitor to treatment with Faslodex improved survival among women with hormone receptor-positive, human epidermal growth factor2-negative advanced breast cancer.

Frontline Tagrisso Improves Survival Among Specific Subgroup of Patients with NSCLC

September 30th 2019

First-line Tagrisso significantly extended overall survival compared with first generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer, according to results from the phase 3 FLAURA study.

Opdivo-Yervoy Combination Induces Long-Term Survival in Metastatic Melanoma

September 29th 2019

One in two patients with metastatic melanoma is alive five years following treatment with Opdivo plus Yervoy, according to long-term follow-up of the phase 3 CheckMate 067 trial.

Frontline Zejula Maintenance Therapy Improves Survival in Advanced Ovarian Cancer

September 29th 2019

Frontline maintenance therapy with Zejula lengthened time without disease progression among women with newly diagnosed, advanced ovarian cancer, according to findings from the phase 3 PRIMA study.

Frontline Opdivo, Yervoy May Improve Survival in Non-Small Cell Lung Cancer

September 29th 2019

First-line treatment with Opdivo plus low-dose Yervoy improved survival among patients with advanced NSCLC compared to chemotherapy, according to results from the CheckMate-227 trial.

Addition of PARP Inhibitor to Maintenance Therapy May Improve Survival in Ovarian Cancer

September 28th 2019

The addition of Lynparza to maintenance therapy with Avastin improved time to disease progression in women with advanced ovarian cancer, according results of the PAOLA-1/ENGOT-ov25 trial.

Erleada May Extend Subsequent Progression in Men With Castration-Resistant Prostate Cancer

September 28th 2019

Morever, the next-generation androgen receptor improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer, according to updated findings of the phase 3 SPARTAN trial.